Risk Paradigm Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Risk Paradigm Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.44M	Buy	21,755 +1,246	+6%	+$168K	2.7%	9
2026 Q1	$2.62M	Buy	20,509 +2,304	+13%	+$288K	2.23%	15
2025 Q4	$2.22M	Buy	+18,205	New	+$2.09M	2.14%	22
2018 Q4	$195K	Buy	2,717 +451	+20%	+$36.3K	0.47%	44
2018 Q3	$217K	Buy	2,266 +597	+36%	+$57.9K	0.43%	45
2018 Q2	$159K	Hold	1,669	–	–	0.31%	47
2018 Q1	$146K	Buy	1,669 +1,028	+160%	+$93.8K	0.19%	96
2017 Q4	$54.4K	Buy	641 +403	+169%	+$33.8K	0.06%	155
2017 Q3	$20.6K	Buy	+238	New	+$19.1K	0.03%	192

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Risk Paradigm Group's XBI Position: Q2 2026 in Review

Risk Paradigm Group increased its State Street SPDR S&P Biotech ETF (XBI) stake by 6.1% in Q2 2026, buying an estimated $168K and bringing the position to 21,755 shares worth $3.44M. The position accounts for 2.7% of the portfolio, ranked #9.

Risk Paradigm Group first reported a position in XBI in Q3 2017 and has held it in 9 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Risk Paradigm Group held 21,755 shares of State Street SPDR S&P Biotech ETF worth $3.44M as of Q2 2026.
Risk Paradigm Group bought 1,246 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $168K.
State Street SPDR S&P Biotech ETF made up 2.7% of Risk Paradigm Group's portfolio in Q2 2026, its #9 holding.
Risk Paradigm Group first reported a position in State Street SPDR S&P Biotech ETF in Q3 2017 and has held it in 9 quarters since.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Risk Paradigm Group's 13F filing for Q2 2026, filed 5 Aug 2026.